ID   HepaRG-CAR
AC   CVCL_XI49
DR   Wikidata; Q94103091
RX   Patent=US20190256822;
RX   PubMed=27780834;
RX   PubMed=32130581;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3291.
CC   Characteristics: Compared to the parent cell line, has improved liver functionality. Drug metabolism is highly improved. Culturing can be performed in serum-free conditions both in the presence or absence of DMSO.
CC   Transfected with: HGNC; 7969; NR1I3.
CC   Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3098; Hepatitis C infection
DI   NCIt; C3099; Hepatocellular carcinoma
DI   ORDO; Orphanet_88673; Hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9720 ! HepaRG
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 29-06-23; Version: 9
//
RX   Patent=US20190256822;
RA   van der Mark V.A.;
RT   "Hepatic cell line resistant to dimethyl sulfoxide, cell culture and
RT   uses thereof.";
RL   Patent number US20190256822, 22-Aug-2019.
//
RX   PubMed=27780834; DOI=10.1124/dmd.116.072603;
RA   van der Mark V.A., de Waart D.R., Shevchenko V., Oude Elferink R.P.J.,
RA   Chamuleau R.A.F.M., Hoekstra R.;
RT   "Stable overexpression of the constitutive androstane receptor reduces
RT   the requirement for culture with dimethyl sulfoxide for high drug
RT   metabolism in HepaRG cells.";
RL   Drug Metab. Dispos. 45:56-67(2017).
//
RX   PubMed=32130581; DOI=10.1007/s10616-020-00384-w;
RA   Adam A.A.A., Jongejan A., Moerland P.D., van der Mark V.A.,
RA   Oude Elferink R.P.J., Chamuleau R.A.F.M., Hoekstra R.;
RT   "Genome-wide expression profiling reveals increased stability and
RT   mitochondrial energy metabolism of the human liver cell line
RT   HepaRG-CAR.";
RL   Cytotechnology 72:377-395(2020).
//